Adequate consumption of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is associated with favorable health outcomes, but 90% of U.S. adults do not meet the recommended intake. Supplementation of EPA and DHA is a promising avenue for mitigating this shortfall. Not surprisingly, the market is constantly looking for ways to boost EPA and DHA absorption.

A new study published in the journal Nutrition assessed the bioavailability of EPA and DHA in a phospholipid-enhanced fish oil (PEFO) product compared to a traditional krill oil (KO) product in healthy adults.

Join us on August 24 for a discussion with Kevin C. Maki, Ph.D., founder and chief scientist for Midwest Biomedical Research, on the recent results of the study. We’ll dig into the findings and discuss the questions they raise.